Lotte Holdings leads pre-seed round in ClearideBio Therapeutics
What's the deal? Lotte Holdings, the Tokyo-based conglomerate, has made its first European biotech investment through its corporate venture capital arm, leading a pre-seed round in ClearideBio Therapeutics. The Swiss startup, founded in December 2025 and headquartered in Basel, is developing next-generation antibody-drug conjugates (ADCs) to treat solid tumours.
ClearideBio's technology platform combines antibody engineering with novel payload and conjugation strategies aimed at improving the safety and efficacy of ADC therapies. It is currently advancing its lead preclinical programme toward initial clinical development, with the goal of entering first-in-human studies in the coming years.
"ClearideBio represents precisely the kind of early-stage, science-driven company we are passionate about supporting through our CVC activities," said Dr Joon Paek, managing partner of Lotte Holdings Healthcare & Biopharmaceutical CVC. "This is an exceptional group of scientists and operators."
Why now? ADCs have become one of the hottest areas in oncology drug development, with major pharma companies racing to acquire or partner with startups working on next-generation designs. ClearideBio is positioning itself to address shortcomings in current ADC therapies — particularly around toxicity and limited efficacy in certain solid tumour types.
For Lotte Holdings, the deal signals a broader push beyond its traditional strengths in food, retail, and hospitality. The conglomerate, which operates across roughly 35 countries, has been expanding into biopharmaceuticals and healthcare as part of its long-term diversification strategy.
What could go wrong? ClearideBio is preclinical-stage, meaning it faces years of development and significant scientific risk before any therapy could reach patients. ADC development is notoriously complex — many candidates fail in clinical trials due to toxicity or insufficient efficacy.
As a pre-seed investment, the financial risk is high. The company will need substantial follow-on funding to progress through clinical trials, and there is no guarantee it will attract later-stage investors in what remains a competitive fundraising environment for early biotech.
The signal: Corporate venture capital from non-pharma conglomerates flowing into early-stage biotech is a notable trend. It suggests that diversified companies like Lotte see healthcare and biopharma as critical growth vectors — and are willing to take on pre-seed risk to secure a foothold.
The deal also highlights Basel's enduring pull as a biotech hub and Europe's growing appeal for Asian CVC capital seeking innovation outside domestic markets.
Read more: nasdaq.einnews.com
